Two Cases of Atypical Presentation of Papillary Fibroelastoma

Presentación atípica de dos casos de fibroelastoma papilar

To the Editor,

The finding of a small rounded mass over an undiseased valve, with no signs of endocarditis, points to the diagnosis of fibroelastoma. Given the high degree of suspicion provided by these types of images, some authors are in favor of a watchful waiting approach. However, fibroelastomas do not always present in this way, and decision making can be complex.

We present 2 cases of presentation at an atrial site. The first corresponds to a 76-year-old man who was admitted for a first episode of heart failure. He had no constitutional or infectious signs and symptoms. Severe mitral valve regurgitation was apparent in the transthoracic echocardiogram. The transesophageal study showed prolapse affecting scallops 2 and 3 of the posterior leaflet. In addition, a homogeneous mobile mass of 1 × 2 cm was found by chance, located on a broad pediculum, adhered to the atrial endocardium and close to the mitral annulus (Fig. 1). Neither the valve nor the atrial appendage was involved, but both were increased in size and free of masses. The patient underwent mitral repair and the mass was excised. Pathological examination revealed a 2 cm fragment of pearl-colored, “villiferous”-looking tissue. Under the microscope, this form appeared as an avascular papillary tumor with multiple digitiform fronds comprised of dense connective tissue with low cellularity over a matrix of mucopolysaccharides, elastic fibers, and spindle cells, all covered by a layer of hyperplastic endocardial cells (Fig. 1).

The second case corresponds to a 55-year-old woman with no prior relevant history who was referred for a finding of atrial mass during gastroenterological endoscopy. Transesophageal echocardiography showed a highly mobile mass of 2.5 cm, with a broad stalk, adhered to the posterior endocardium of the left atrium, which was of normal size and morphology (Fig. 2). Although the patient was asymptomatic, the mass was removed given its large size and mobility; the pathology report revealed similar histological characteristics to those described for the first case (Fig. 2).

Papillary fibroelastoma was described by Yater in 1931. It is the third most common cardiac tumor after myxoma and lipoma, and the one that most frequently affects the cardiac valves. There are many theories about its origin: organized thrombus, hamartoma, hyperplastic reaction to external agents, or a form of chronic viral endocarditis. Most tumors remain asymptomatic, and so their prevalence is underestimated. In the left-side chambers, they may present as systemic embolism, with cerebral ischemia being the most frequent; right-side embolism is less frequent although acute pulmonary embolism or chronic pulmonary hypertension may occur.

The preferred site is the endocardial valve, accounting for 75% of cases, and the aortic valve, with no preference for which side, is the most widely affected, followed by the mitral valve (atrial side) and to a lesser extent the tricuspid and pulmonary valves. At these sites, the tumors are usually rounded and small. The presence in the image of these characteristics, without any
signs of endocarditis, leads to a strong suspicion of fibroelastoma. However, approximately one-fourth of the cases are anchored to the nonvalvar endocardium and the left ventricle is the most frequently affected site. In echocardiography, these tumors show up as mobile digitiform masses, with several villous structures originating from a stalk anchored to the endocardium. Involvement of the endocardial surface of the left atrium accounts for 1.5% to 9.5% of cases in different series, and the tumors are small, usually <1 cm. Our cases presented with a similar echocardiographic appearance: lobulated, highly mobile, homogeneous masses >2 cm, with a broad stalk, adhered to the endocardium of the left atrium. These atypical characteristics of papillary fibroelastoma required a differential diagnosis, essentially with a thrombus (likely in the absence of emboligenic structural heart disease) and with atrial myxoma. Given the similarities of our cases, we propose that the finding of a cardiac mass with the echocardiographic characteristics described above, and in the absence of emboligenic heart disease, provided diagnostic suspicion of papillary fibroelastoma at an atypical site.

Four years separated diagnosis of the 2 cases. Since 2000, 13 cases of echocardiographic suspicion of fibroelastoma have been included in our database. Apart from the 2 cases described here, the remaining 11 had a typical site and typical characteristics. Only 3 tumors were resected, and diagnosis of fibroelastoma was confirmed in 2. The 8 remaining patients are undergoing regular follow-up with imaging techniques.

When embolism is diagnosed, the whole tumor tends to be removed to avoid embolic recurrences. There is less agreement for asymptomatic tumors. If the mass is large and mobile, there is consensus about surgical resection if valve replacement is not necessary. However, in cases of typical valve location, small size (1 cm), and lack of excessive mobility, watchful waiting with anticoagulation therapy is considered appropriate.

These recommendations do not, however, apply for fibroelastomas at atypical sites. The reasonable approach when faced with such masses is to rule out as many diagnoses as possible by noninvasive means. Gradual enhancement of magnetic resonance data may help in tumor diagnosis. Once diagnosed, surgical resection (provided the risk is not too high) can provide an indication of etiology, prognostic evaluation, and specific treatment.

Sem Briongos Figuero,a,*, Héctor Gerardo Pian,b José Luis Moya Mur,c and Ramón Fernández Espino,b

Servicio de Imagen Cardiaca, Instituto de Enfermedades Cardiovasculares, Hospital Ramón y Cajal, Madrid, Spain
Servicio de Anatomía Patológica, Hospital Ramón y Cajal, Madrid, Spain

*Corresponding author:
E-mail address: Semdoc@hotmail.com (S. Briongos Figuero).
Available online 31 July 2011

REFERENCES


Proarrhythmic Potential of Amiodarone: An Underestimated Risk?

Potencial proarritmico de la amiodarona: ¿un riesgo subestimado?

To the Editor,

Because of its known safety and efficacy, amiodarone is a first-line drug for the treatment of atrial and ventricular arrhythmias in patients with structural heart disease. Its proarrhythmic side effects are usually underestimated because they are less common than those experienced with other antiarrhythmic drugs. We describe a case of corrected QT interval prolongation (QTc) and torsade de pointes (Tdp) secondary to amiodarone.

A 59-year-old woman with hypertension and chronic obstructive pulmonary disease with a significant bronchospastic component was attended at home for palpitations and dizziness. The electrocardiogram (ECG) showed self-limiting, regular, wide-QRS tachycardia at a rate of 210 bpm before admission and sinus rhythm at a rate of 90 bpm with a QRS duration of 90 ms and QTc of 415 ms on hospital admission (Fig. 1A). The cardiologic study revealed dilated cardiomyopathy with moderate ventricular dysfunction, but no major coronary lesions.

On the third day of hospitalization, the patient experienced well-tolerated sustained monomorphic ventricular tachycardia (SMVT) at a rate of 270 bpm (Fig. 2A) that reverted once intravenous perfusion of amiodarone was initiated.

Twenty-four hours later, the patient presented an episode of Tdp that degenerated into ventricular fibrillation, which was treated by electrical cardioversion (Figs. 2B and C), and therefore she was transferred to our hospital.

The ECG on admission showed sinus rhythm at a rate of 75 bpm with a QRS duration of 146 ms and QTc of 714 ms (Fig. 1B). The patient presented no other recognizable factors that prolong QTc interval, except discrete hypopotassemia (3.2 mEq/L).

Although amiodarone was discontinued and potassium and magnesium supplements were given, she experienced 11 new episodes of Tdp, which were controlled by implantation of a temporary ventricular pacemaker at 100 bpm (Fig. 1C) for 4 days. A week after amiodarone discontinuation, the QRS measured 110 ms and the QTc, 449 ms (Fig. 1D).

In view of the well tolerated SMVT episodes and the moderate nonischemic ventricular dysfunction, an electrophysiologic study was performed in which clinical SMVT originating in the apical lateral region of the left ventricle was induced and the circuit was ablated.

Amiodarone acts by blocking different ion channels involved in the action potential, which makes it effective for the treatment of various arrhythmias. The drug’s dominant effect is class III, as it blocks potassium channels during repolarization and therefore can prolong the QTc interval. QTc elongation is known to be the predisposing factor for the appearance of Tdp, and although amiodarone can prolong the QTc few reports of amiodarone-induced Tdp have been published.